Dr. Sidana is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2018 - 2019- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2015 - 2018
Cleveland Clinic FoundationResidency, Internal Medicine, 2012 - 2015
Maulana Azad Medical CollegeClass of 2011
Certifications & Licensure
CA State Medical License 2019 - 2025
MN State Medical License 2015 - 2019
OH State Medical License 2012 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma Start of enrollment: 2020 Oct 05
Publications & Presentations
PubMed
- 79 citationsInternational harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.Luciano J. Costa, Benjamin A. Derman, Susan Bal, Surbhi Sidana, Saurabh Chhabra
Leukemia. 2021-01-01 - 43 citationsEarly cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.Jennifer M Logue, Lauren C Peres, Hamza Hashmi, Christelle M Colin-Leitzinger, Alexandria M Shrewsbury
Blood Advances. 2022-12-27 - 290 citationsCAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trialJay Y. Spiegel, Shabnum Patel, Lori Muffly, Nasheed Hossain, Jean Oak
Nature Medicine. 2021-07-26
Journal Articles
- Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of RelapseAngela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature
- Primary Systemic Amyloidosis in Patients with Waldenström MacroglobulinemiaAngela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
Abstracts/Posters
- Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep ResponsesSurbhi Sidana, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL AmyloidosisSurbhi Sidana, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT).ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Cilta-Cel Treatment Safe, Effective for Relapsed/Refractory Multiple MyelomaOctober 9th, 2024- Cilta-Cel Treatment Safe, Effective for Relapsed/Refractory Multiple MyelomaOctober 9th, 2024
- Real World CAR T-cell Therapy Outcomes 'Favorable' in Relapsed/Refractory MyelomaOctober 4th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
